Moleculin net loss narrows to $7.64 million in Q2 FY26; R&D expense rises to $5.45 million
Reuters2026/08/13 20:28- Moleculin Biotech posted a net loss of USD 7.64 million in Q2 2026, narrowing from a USD 17.81 million loss a year earlier.
- Operating loss widened to USD 7.56 million as research and development expense rose 52.78% to USD 5.45 million.
- For the first half, net loss narrowed to USD 20.48 million from USD 23.71 million, helped by a USD 10.76 million warrant fair-value gain.
- Cash used in operating activities increased to USD 12.77 million in the first six months, while financing cash inflows fell to USD 11.23 million.
- MIRACLE trial enrollment reached 76 of 90 as of Aug. 6; Part A unblinding is expected between December 2026 and February 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The first major "exam" after the Cook era! Morgan Stanley: Apple's (AAPL.US) autumn launch event is the most important in ten years; the first foldable iPhone may spark a new wave of growth
Morgan Stanley analysts stated that Apple's upcoming "Surprise and Shine" autumn product launch event on September 9 may become the company's most important product release in nearly a decade.
For the first time in over a year, the open interest share of altcoins has surpassed that of bitcoin.
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Crypto prices
More
